Med-IQ Logo
Get CME/CE
Viewpoints on Atopic Dermatitis: How Emerging Treatments May Change the Management of Moderate-to-Severe Disease
E-Publication E-Publication

Viewpoints on Atopic Dermatitis: How Emerging Treatments May Change the Management of Moderate-to-Severe Disease


Time to Complete:
30 minutes
Released:
7/21/17
Expires:
7/20/18

Maximum Credits:

0.5 AMA PRA Category 1 Credit(s)
By clicking "Start," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Policy and Terms of Service.

E-Publication E-Publication
By clicking "Start," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Policy and Terms of Service.
Time to Complete:
30 minutes

Released:
7/21/17

Expires:
7/20/18

Maximum Credits:
0.5 AMA PRA Category 1 Credit(s)
Share on:
E-Publication E-Publication
By clicking "Start," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Policy and Terms of Service.

Share on:


Time to Complete:
30 minutes
Released:
7/21/17
Expires:
7/20/18


Maximum Credits:
0.5 AMA PRA Category 1 Credit(s)


Overview: This interactive CME publication reviews current clinical evidence on the use of novel agents targeting cytokine signaling for the systemic treatment of moderate-to-severe atopic dermatitis (AD). Survey responses from community allergists and dermatologists regarding these agents are integrated with expert insights on key survey findings.

Faculty

Erwin W. Gelfand, MD

Professor of Pediatrics

Division of Pediatric Allergy and Clinical Immunology

University of Colorado School of Medicine

National Jewish Health

Denver, CO

Emma Guttman-Yassky, MD, PhD

Professor of Dermatology and Immunology

Director of the Center for Excellence in Eczema

Director of the Laboratory of Inflammatory Skin Diseases

Icahn School of Medicine

Mount Sinai Medical Center

New York, NY


Disclosure Policy

Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.


Disclosure Statement

The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.  

Erwin W. Gelfand, MD
Consulting fees/advisory boards: Regeneron Pharmaceuticals, Inc., Respira Therapeutics, Inc.
 
Emma Guttman-Yassky, MD, PhD
Consulting fees/advisory boards: AbbVie Inc., Allergan, Inc., Amgen, Anacor Pharmaceuticals, Inc., Bristol-Myers Squibb, Celgene Corporation, Dermira, Drais Pharmaceuticals, Inc., Eli Lilly and Company, Escalier Biosciences, Galderma Laboratories, L.P., Genentech, GlaxoSmithKline, LEO Pharma, Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi-aventis U.S. Inc., Vitae Pharmaceuticals, Inc.

The writer, peer reviewers, and activity planners have no financial relationships to disclose.


This activity has been approved for AMA PRA Category 1 Credit™.


This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.
Play Video
The trifecta of healthcare improvement: value-based care, quality improvement, and technology.

See how Med-IQ is helping to enhance patient outcomes in these short videos.

Scott Weber, CEO Med-IQ

From Volume to Value-Based Care: The Role of the CME Enterprise

Scott Weber, CEO,
Med-IQ

Allison Gardner, PhD, VP Educational Strategy and Content, Med-IQ

The Value of Quality Improvement and Education to Advance Healthcare

Allison Gardner, PhD,
VP Educational Strategy and Content,
Med-IQ

Dr. Glenn Treisman,
Department of Psychiatry, Johns Hopkins Medical Institute

The Pros and Cons of Technology on the Practice of Medicine

Dr. Glenn Treisman,
Department of Psychiatry,
Johns Hopkins Medical Institute


Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or e-mail info@med-iq.com. For technical assistance, please refer to our support manual.